Sale

Generic Oncology Drugs Market

Global Generic Oncology Drugs Market Size, Share, Trends: By Molecule Type: Large Molecule, Small Molecule; By Route of Administration: Oral, Parentals; By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy; Regional Analysis; Patent Analysis; Grants Analysis; Supplier Landscape; 2024-2032

Global Generic Oncology Drugs Market Outlook

The global generic oncology drugs market value was USD 26.87 billion in 2023, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 6.2% during the forecast period of 2024-2032 to achieve a value of USD 46.17 billion by 2032.

 

Global Generic Oncology Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global generic oncology drugs market is being driven by the growing cancer incidences across the globe coupled with rising demand for such drugs to assist patients undergoing chemotherapy, alleviating after-effects, including pain. 

Region-wise, North America is the leading market for generic oncology drugs accounting for the majority of the global share. The growth of the market in the region can be attributed to the availability of advanced technology and enhanced healthcare infrastructure. On the other hand, the Asia Pacific is expected to be one of the emerging markets owing to the increased government expenditure in the healthcare sector in the region coupled with the presence of increased population.

 

Market Segmentation

Generic oncology drugs refer to the drugs that assist in shrinking, controlling, and eliminating the cancer cells present in the human body. They perform a pivotal role in cancer treatment as some of the anti-cancer drugs are only available in the form of generics. Generic oncology drugs share similar active ingredients as the already marketed brand-name cancer care medicine, and they can be characterised by different colours or flavours in comparison to the original drugs. The performance, intended use, quality, dosage form, and route of administration of these drugs are similar to that of their original counterparts.

The EMR report has analysed the major regional markets in the industry, which are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Market Analysis

The generic oncology drugs market is driven by the growing prevalence of cancer across the globe, coupled with high costs associated with cancer treatment. These drugs are bioequivalent of and are used as an alternative means to brand-name medicines, providing similar pharmacological effects in cancer treatment. A rapid increase in the number of smokers, coupled with a rise in sedentary and unhealthy lifestyles, has increased the incidences of cancer cases around the world. As a result of this, there has been an acceleration in the demand for cost-effective and viable cancer treatments, including generic oncology drugs. Increasing adulteration in food products and the usage of pesticides in fresh fruits and vegetables has injected a lot of chemicals in the human body responsible for such diseases.

Apart from this, rising government expenditure in the emerging nations to promote generic drugs and reduce healthcare expenses is positively influencing the regional market growth. Furthermore, rapid advancements in the healthcare sector and biotechnology and research field have resulted in early and affordable cancer diagnosis, thus increasing the demand for generic oncology drugs at the prevention stage. Thus, rising geriatric population and growing demand for cost-effective treatment procedures, particularly in emerging regions are aiding the industry further.

Factors such as new product launches and benefits offered by generic drugs are boosting the market. In addition, the growing pharmaceutical industry in developing countries is likely to have a positive impact on the growth of the market in the coming years. The ongoing research and development activities are aiding the market growth. Moreover, the leading players in the market are innovating and launching enhanced products, which is expected to have a positive effect on the industry growth over the forecast period.

 

Generic Oncology Drugs Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report gives a detailed analysis of the following key players in the global generic oncology drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Mylan N.V.
  • Hikma Pharmaceuticals PLC
  • Stason Pharmaceuticals
  • Mayne Pharma
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Molecule Type
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Molecule Type
  • Large Molecule
  • Small Molecule
Breakup by Route of Administration
  • Oral
  • Parentals
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Merk & Company, Inc.
  • Aurobindo Pharma.
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • NATCO Pharma Limited
  • CELGENE CORPORATION
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Cancer Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Cancer Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Cancer Epidemiology (2016-2031)
    5.3    Europe Cancer Epidemiology (2016-2031)
    5.4    Asia-Pacific Cancer Epidemiology (2016-2031)
    5.5    Latin America Cancer Epidemiology (2016-2031)
    5.6    Middle East & Africa Cancer Epidemiology (2016-2031)
6    Global Generic Oncology Drugs Market Overview 
    6.1    Global Generic Oncology Drugs Market Historical Value (2017-2023) 
    6.2    Global Generic Oncology Drugs Market Forecast Value (2024-2032)
7    Global Generic Oncology Drugs Market Landscape
    7.1    Global Generic Oncology Drugs Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Generic Oncology Drugs Product Landscape
        7.2.1    Analysis by Molecule 
        7.2.2    Analysis by Route of Administration
        7.2.3    Analysis by Distribution Channel
8    Generic Oncology Drug Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Generic Oncology Drugs Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model 
    10.4    Key Demand Indicators
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends 
    10.7    Value Chain Analysis
11    Global Generic Oncology Drugs Market Segmentation 
    11.1    Global Generic Oncology Drugs Market by Molecule Type
        11.1.1    Market Overview
        11.1.2    Large Molecule
        11.1.3    Small Molecule
    11.2    Global Generic Oncology Drugs Market by Route of Administration
        11.2.1    Market Overview
        11.2.2    Oral
        11.2.3    Parentals
    11.3    Global Generic Oncology Drugs Market by Distribution Channel
        11.3.1    Market Overview
        11.3.2    Hospital Pharmacy
        11.3.3    Online Pharmacy
        11.3.4    Retail Pharmacy
    11.4    Global Generic Oncology Drugs Market by Region
        11.4.1    Market Overview
        11.4.2    North America 
        11.4.3    Europe
        11.4.4    Asia Pacific
        11.4.5    Latin America
        11.4.6    Middle East and Africa
12    North America Generic Oncology Drugs Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Generic Oncology Drugs Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Generic Oncology Drugs Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Generic Oncology Drugs Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Generic Oncology Drugs Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year 
    19.2    Analysis by Trial Status 
    19.3    Analysis by Trial Phase 
    19.4    Analysis by Therapeutic Area 
    19.5    Analysis by Geography 
20    Funding Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Regulatory Framework
    22.1    Regulatory Overview
        22.1.1    US FDA
        22.1.2    EU EMA
        22.1.3    INDIA CDSCO
        22.1.4    JAPAN PMDA
        22.1.5    Others
23    Supplier Landscape
    23.1    Novartis AG
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Pfizer Inc.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    GlaxoSmithKline plc
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Teva Pharmaceutical Industries Ltd.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Merk & Company, Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Aurobindo Pharma.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Hikma Pharmaceuticals PLC
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Mylan N.V.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    NATCO Pharma Limited
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    CELGENE CORPORATION
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
24    Global Generic Oncology Drugs Market - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market of generic oncology drugs attained a value of USD 26.87 billion.

The market is anticipated to grow at a CAGR of 6.2% during the forecast period of 2024-2032 to reach a value of USD 46.17 billion by 2032.

The major drivers of the industry include rising disposable incomes, increasing population, rising cancer incidences, rising demand for these drugs to assist patients undergoing chemotherapy, alleviating after-effects, including pain, availability of advanced technology and enhanced healthcare infrastructure.

The increased government expenditure in the healthcare industry is expected to be a key trend guiding the growth of the industry.

North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market, with North America accounting for the largest market share.

The leading players in the market are Mylan N.V., Hikma Pharmaceuticals PLC, Stason Pharmaceuticals, and Mayne Pharma, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER